Where others have failed will Atl1102 succeed ?, page-876

Found the Spark Plus video from March 2021. @samfiodiving @George1972 @waynesworld

This is GOLD - Mark's best ever performance.

Let me quote Mark at 43:18

"You can see the quote from one of our DMD experts based in the UK, Prof Thomas Voit - He's going to be our PI in the Phase IIB clinical trial......"

We were not hearing things - Mark definitely said Prof Voit was going to be PI for EMA trial.

Prof Voit was very excited about ATL1102 results when interviewed by Shane Story from Wilsons.

Prof Voit is also part owner of the patent Sarepta are using for "micro-dystrophin".

Join the dots and we get: Combination Therapy....firstly with Exondys51 then with Gene Therapy.

47:07 - Mark makes reference to Sarepta's GT failure.

51:40 - Mark throws shade at Sarepta's efficacy

49:10 - New indications.

20210326 - Spark Plus Q1 BioTech Day - YouTube